Open Access
Online ISSN: 2992-5487
Print ISSN: 2992-6068

NIJEP Publications

NEWPORT INTERNATIONAL JOURNAL OF ENGINEERING AND PHYSICAL SCIENCES (NIJEP)

Volume 6 Issue 1 Page 30-37, 2026

https://doi.org/10.59298/NIJEP/2026/613037

Nanotechnology-Driven Delivery of Natural Anti-Inflammatory Compounds for Obesity Management

Mugisha Emmanuel K.

Faculty of Science and Technology Kampala International University Uganda

ABSTRACT

Obesity is increasingly recognized as a chronic inflammatory condition that underlies insulin resistance, metabolic syndrome, type 2 diabetes, and cardiovascular disease. Persistent low-grade inflammation, particularly within white adipose tissue, is driven by adipocyte dysfunction, immune cell infiltration, oxidative stress, and dysregulated adipokine signaling. Natural anti-inflammatory compounds derived from dietary and medicinal plants, such as polyphenols, flavonoids, terpenoids, and alkaloids, have demonstrated significant potential in attenuating obesity-associated inflammation and improving metabolic outcomes. However, their clinical translation is limited by poor solubility, low bioavailability, rapid metabolism, and a lack of tissue specificity. Nanotechnology-driven drug delivery systems offer innovative solutions to overcome these limitations by enhancing stability, bioavailability, and targeted delivery of natural bioactives. Nanocarriers such as polymeric nanoparticles, lipid-based systems, nanoemulsions, and nanomicelles enable controlled and site-specific release of natural compounds, maximizing therapeutic efficacy while minimizing systemic side effects. This review comprehensively examines the pathophysiological basis of inflammation in obesity, the anti-inflammatory mechanisms of natural compounds, and the role of nanotechnology in optimizing their delivery. Current advances, therapeutic applications, translational challenges, and future perspectives are discussed, highlighting nanotechnology-enabled natural therapeutics as a promising strategy for sustainable and personalized obesity management.

Keywords: Nanotechnology; Natural anti-inflammatory compounds; Obesity; Adipose tissue inflammation; Drug delivery systems

INTRODUCTION

Obesity has emerged as a major global health burden, with its prevalence increasing at an unprecedented rate across both developed and developing regions[1–4]. Beyond excessive fat accumulation, obesity is now widely regarded as a chronic inflammatory disease that predisposes individuals to insulin resistance, metabolic syndrome, type 2 diabetes, cardiovascular disease, and certain cancers. Central to obesity pathogenesis is persistent low-grade inflammation, particularly within white adipose tissue, which disrupts metabolic homeostasis and accelerates disease progression[5, 6].

In healthy individuals, white adipose tissue functions as a dynamic endocrine organ, regulating energy balance, lipid storage, and glucose metabolism through the secretion of adipokines such as adiponectin and leptin[7]. In obesity, adipocyte hypertrophy, hypoxia, oxidative stress, and cellular apoptosis trigger immune cell infiltration, especially pro-inflammatory macrophages[8–11]. These immune cells release cytokines, including tumor necrosis factor-α, interleukin-6, and interleukin-1β, which impair insulin signaling pathways and promote systemic inflammation. This chronic inflammatory environment establishes a vicious cycle linking adipose dysfunction to metabolic disease[12, 13].

Current pharmacological approaches for obesity and its complications primarily target appetite regulation, lipid metabolism, or glucose homeostasis. While effective in some cases, these treatments often exhibit limited long-term efficacy, undesirable side effects, and poor patient adherence[14, 15]. As a result, there is growing interest in alternative and complementary therapeutic strategies that are safer, more sustainable, and capable of addressing the inflammatory roots of obesity.

Open Access
Online ISSN: 2992-5487
Print ISSN: 2992-6068
NIJEP Publications

Natural anti-inflammatory compounds derived from plants and dietary sources have attracted significant attention in this context. Polyphenols such as curcumin, resveratrol, quercetin, and catechins; flavonoids; carotenoids; terpenoids; and alkaloids have demonstrated potent anti-inflammatory, antioxidant, and insulin-sensitizing effects in preclinical and clinical studies[16, 17]. These compounds modulate key inflammatory pathways, including NF-κB, MAPK, and JNK signaling, while enhancing mitochondrial function and adipokine balance.

Despite their therapeutic promise, the clinical application of natural anti-inflammatory compounds is severely limited by unfavorable physicochemical and pharmacokinetic properties[18]. Many natural bioactives exhibit poor aqueous solubility, low oral bioavailability, rapid metabolic degradation, and limited tissue targeting. Consequently, high doses are often required to achieve therapeutic effects, increasing the risk of off-target toxicity and reducing translational feasibility[18].

Nanotechnology-driven delivery systems offer transformative solutions to these challenges. Nanocarriers can encapsulate natural compounds, protect them from degradation, enhance absorption, prolong circulation time, and enable targeted delivery to inflamed adipose tissue. Furthermore, nanotechnology allows controlled and stimuli-responsive drug release, ensuring that therapeutic agents are released preferentially within inflammatory microenvironments[19, 20]. This review explores the role of nanotechnology in enhancing the delivery and efficacy of natural anti-inflammatory compounds for obesity management. We discuss the molecular basis of obesity-associated inflammation, the anti-inflammatory mechanisms of natural bioactives, nanocarrier design strategies, therapeutic applications, and key challenges hindering clinical translation.

2. Inflammation as a Therapeutic Target in Obesity

Chronic inflammation is a defining feature of obesity and a critical driver of its metabolic complications. Unlike acute inflammation, obesity-associated inflammation is persistent, low-grade, and systemic, yet sufficient to disrupt insulin signaling and metabolic homeostasis[7, 12, 21, 22]. White adipose tissue is the primary site of inflammatory initiation, although secondary involvement of the liver, skeletal muscle, pancreas, and vasculature amplifies disease severity.

Adipocyte hypertrophy induces hypoxia and mechanical stress, leading to the activation of stress-responsive signaling pathways and the release of pro-inflammatory mediators. Dead or dysfunctional adipocytes attract macrophages, which adopt a pro-inflammatory M1 phenotype and form crown-like structures within adipose tissue[3, 21, 23, 24]. These macrophages secrete cytokines and chemokines that exacerbate inflammation and recruit additional immune cells.

Inflammatory signaling pathways such as nuclear factor kappa B, c-Jun N-terminal kinase, and mitogen-activated protein kinases play central roles in mediating insulin resistance[25]. These pathways inhibit insulin receptor substrate phosphorylation, reduce glucose uptake, and promote lipolysis, resulting in elevated circulating free fatty acids that further propagate inflammation.

Targeting inflammation has therefore emerged as a promising strategy for obesity management. Natural anti-inflammatory compounds offer advantages over synthetic drugs due to their multitargeted mechanisms, antioxidant properties, and favorable safety profiles. However, effective modulation of adipose tissue inflammation requires sufficient bioavailability and targeted delivery, underscoring the importance of advanced drug delivery systems.

3. Natural Anti-Inflammatory Compounds with Anti-Obesity Potential

A wide range of natural compounds have been identified with potent anti-inflammatory and anti-obesity properties, making them attractive candidates for the prevention and management of obesity-related metabolic disorders. These bioactive molecules act through multiple molecular pathways to suppress chronic inflammation, improve insulin sensitivity, and restore metabolic balance. Among them, polyphenols have received substantial attention due to their broad spectrum of biological activities[26, 27]. Curcumin and resveratrol, for example, are well known for their ability to inhibit pro-inflammatory cytokines such as tumor necrosis factor-α and interleukin-6, while simultaneously enhancing insulin signaling pathways[28–30]. By modulating key transcription factors involved in inflammation and glucose metabolism, these polyphenols contribute to improved glycemic control and reduced adipose tissue inflammation.

Flavonoids represent another important class of natural anti-obesity compounds. Molecules such as quercetin and kaempferol have been shown to inhibit macrophage infiltration into adipose tissue, a hallmark of obesity-induced inflammation[31]. These flavonoids also exert strong antioxidant effects, reducing oxidative stress and protecting adipocytes from inflammatory damage. By limiting reactive oxygen species production, they help preserve adipocyte function and prevent the progression of metabolic dysfunction[32, 33]. Catechins derived from green tea further complement these effects by enhancing lipid oxidation, promoting energy expenditure, and attenuating adipogenesis. Their ability to regulate lipid metabolism contributes to reduced fat accumulation and improved body weight control[34, 35].

Terpenoids and carotenoids add another layer of metabolic regulation by interacting with nuclear receptors such as peroxisome proliferator-activated receptor gamma (PPARγ). Through this mechanism, they influence

adipocyte differentiation, lipid storage, and insulin sensitivity, thereby supporting overall metabolic balance[36, 37]. Alkaloids and phenolic acids also play important roles by modulating anti-inflammatory signaling pathways and preserving mitochondrial integrity. By protecting mitochondrial function, these compounds enhance cellular energy metabolism and reduce inflammation-driven metabolic stress[27, 38, 39].
Collectively, these natural compounds exert coordinated effects on adipokine secretion, favorably regulating hormones such as adiponectin and leptin that are critical for metabolic homeostasis. They also improve communication along the gut–adipose axis, influencing gut microbiota composition and intestinal barrier function, which further contributes to systemic metabolic health.

Despite the robust evidence from preclinical studies supporting their efficacy, the clinical translation of these natural compounds remains limited. Poor aqueous solubility, chemical instability, and rapid metabolism significantly reduce their bioavailability and therapeutic effectiveness in humans. As a result, nanotechnology-based delivery systems have become essential tools for overcoming these barriers[20, 40, 41]. By enhancing stability, improving absorption, and enabling targeted delivery, nanocarriers offer a promising strategy to unlock the full therapeutic potential of natural anti-inflammatory and anti-obesity compounds.

4. Nanotechnology Platforms for Delivering Natural Anti-Inflammatory Compounds

Nanotechnology offers a wide range of versatile platforms for improving the delivery, stability, and therapeutic efficacy of natural bioactive compounds, particularly in the context of chronic inflammatory and metabolic disorders[42, 43]. Many natural compounds with proven anti-inflammatory, antioxidant, or metabolic regulatory properties suffer from poor solubility, rapid degradation, low bioavailability, and nonspecific distribution. Nanotechnology-based delivery systems address these limitations by protecting bioactives from premature degradation, enhancing their absorption, and enabling controlled and targeted release at disease sites.
Polymeric nanoparticles are among the most widely explored nanocarriers for natural bioactives. Constructed from biodegradable and biocompatible polymers such as poly(lactic-co-glycolic acid), chitosan, and alginate, these nanoparticles offer excellent control over drug loading and release kinetics[44–46]. By encapsulating bioactive compounds within a polymeric matrix, they protect sensitive molecules from enzymatic degradation and harsh physiological environments. Sustained and controlled release profiles help maintain therapeutic concentrations over extended periods, reducing dosing frequency and improving treatment compliance.
Lipid-based delivery systems, including liposomes and nanostructured lipid carriers, provide additional advantages for the delivery of hydrophobic natural compounds[19, 47, 48]. Liposomes, composed of phospholipid bilayers, closely mimic biological membranes, resulting in high biocompatibility and low immunogenicity. They enhance the solubility of poorly water-soluble bioactives and facilitate cellular uptake. Nanostructured lipid carriers, which combine solid and liquid lipids, offer improved drug loading capacity and stability compared with traditional solid lipid nanoparticles. These systems are particularly effective in enhancing oral and parenteral delivery of natural compounds while minimizing systemic toxicity[49].
Nanoemulsions and nanomicelles further expand the nanotechnology toolbox by significantly improving intestinal absorption and systemic bioavailability[50]. Nanoemulsions consist of fine oil-in-water or water-in-oil dispersions stabilized by surfactants, allowing efficient solubilization of lipophilic bioactives. Nanomicelles, formed by the self-assembly of amphiphilic molecules, encapsulate hydrophobic compounds within their core, protecting them during gastrointestinal transit. Both systems facilitate enhanced permeability across intestinal barriers, leading to improved plasma concentrations and therapeutic outcomes[50].
Beyond carrier design, surface functionalization plays a critical role in enhancing therapeutic precision. By modifying nanoparticle surfaces with targeting ligands such as peptides, antibodies, or small molecules, nanocarriers can selectively accumulate in inflamed adipose tissue through specific ligand–receptor interactions[51]. This targeted approach increases local drug concentration at pathological sites while reducing off-target exposure and systemic side effects.
Stimuli-responsive nanocarriers represent another advanced strategy for precision drug delivery. These systems are engineered to release their payload in response to specific microenvironmental cues such as acidic pH, elevated levels of reactive oxygen species, or increased enzymatic activity commonly found in inflamed tissues[52–54]. Triggered release ensures that bioactive compounds are delivered at the right place and time, maximizing therapeutic efficacy and minimizing unintended toxicity.
Collectively, these nanotechnology-based strategies significantly enhance the delivery of natural bioactives, improve therapeutic accuracy, and reduce systemic toxicity. By integrating advanced carrier design, targeting mechanisms, and stimuli-responsive features, nanotechnology paves the way for safer, more effective, and personalized interventions for inflammation-driven metabolic disorders.

5. Therapeutic Applications in Obesity Management

Nanotechnology-enabled delivery systems have emerged as a transformative approach for enhancing the therapeutic potential of natural anti-inflammatory compounds in the management of obesity and its associated metabolic complications[55]. Although many bioactive phytochemicals exhibit strong anti-inflammatory and antioxidant properties, their clinical translation has been limited by poor aqueous solubility, low bioavailability, rapid metabolism, and nonspecific tissue distribution. Nanotechnology addresses these challenges by improving

compound stability, optimizing pharmacokinetics, and enabling targeted delivery to inflamed adipose tissue, thereby amplifying therapeutic efficacy while minimizing systemic side effects[43].

Preclinical studies have consistently demonstrated that nanoencapsulated natural compounds exert significant benefits in obesity models. Curcumin, a polyphenol derived from *Curcuma longa*, is one of the most extensively studied agents[56]. When encapsulated within nanoparticles, curcumin shows enhanced bioavailability and sustained release, leading to pronounced reductions in adipose tissue inflammation[56, 57]. These effects are mediated through inhibition of key inflammatory pathways, including NF-κB and pro-inflammatory cytokine signaling. Nano-curcumin treatment has also been associated with improved insulin sensitivity, reduced adipocyte hypertrophy, and attenuation of body weight gain in high-fat diet–induced obesity models[57].

Similarly, resveratrol-loaded nanoparticles have shown superior metabolic benefits compared with free resveratrol. Nanocarrier-based delivery improves resveratrol stability and tissue retention, enabling more effective modulation of adipose inflammation and oxidative stress. These systems promote enhanced glucose uptake, improved insulin signaling, and reduced expression of inflammatory mediators in adipose tissue[58, 59]. Together, nano-curcumin and nano-resveratrol exemplify how nanotechnology can unlock the full therapeutic potential of natural compounds that are otherwise limited by unfavorable pharmacological properties.

Flavonoid-loaded nanoparticles represent another promising class of nanotherapeutics. Flavonoids such as quercetin, naringenin, and catechins possess potent anti-inflammatory and immunomodulatory effects[18, 32, 33]. When delivered via nanocarriers, these compounds can selectively target immune cells within adipose tissue, particularly macrophages. This targeted approach facilitates the reprogramming of macrophage polarization from the pro-inflammatory M1 phenotype toward the anti-inflammatory M2 phenotype. As a result, inflammatory signaling pathways are suppressed, adipose tissue homeostasis is restored, and systemic metabolic inflammation is reduced.

Targeted nanocarriers play a critical role in enhancing drug accumulation within adipose tissue. By functionalizing nanoparticles with adipose-homing peptides or ligands that recognize macrophage-specific receptors, therapeutic agents can be delivered with high precision to inflamed sites. This targeting capability allows for the use of lower drug doses while achieving sustained therapeutic effects, reducing the risk of toxicity and improving treatment adherence. Controlled and prolonged release profiles further contribute to stable anti-inflammatory activity over time.

In addition, combination strategies that integrate multiple natural compounds within a single nanocarrier have gained increasing attention[60]. These approaches exploit synergistic mechanisms, such as concurrent antioxidant, anti-inflammatory, and metabolic regulatory effects, to enhance overall therapeutic efficacy[60]. By simultaneously modulating multiple pathological pathways, combination nanotherapies offer a comprehensive strategy for addressing obesity-driven inflammation and metabolic dysfunction. Collectively, these advances highlight the strong potential of nanotechnology-enabled natural compounds as safe, effective, and scalable interventions for obesity-related inflammatory disorders.

6. Challenges and Translational Considerations

Despite promising advances, several challenges hinder clinical translation. Long-term safety, biodegradability, and nanomaterial accumulation require rigorous evaluation. Manufacturing scalability, regulatory complexity, and inter-individual variability in obesity phenotypes further complicate development.

Standardized assessment frameworks and well-designed clinical trials are essential to validate efficacy and safety. Addressing these challenges will be critical for advancing nanotechnology-driven natural therapeutics into clinical practice.

CONCLUSION

Nanotechnology-driven delivery of natural anti-inflammatory compounds represents a promising and sustainable strategy for obesity management. By enhancing bioavailability, stability, and tissue targeting, nanocarriers overcome key limitations associated with natural bioactives. Advances in nanomaterial design have demonstrated significant potential to attenuate adipose inflammation, improve insulin sensitivity, and restore metabolic homeostasis. However, successful clinical translation will depend on addressing safety, scalability, and regulatory challenges. With continued interdisciplinary research and clinical validation, nanotechnology-enabled natural therapeutics may offer safer, more effective, and personalized approaches for managing obesity and its associated metabolic complications.

REFERENCES

1. Alanazi, A., Craven, A., Spirou, S.V., Santos-Martinez, M.J., Medina, C., Gobbo, O.L.: Nanomedicine as a Promising Treatment Approach for Obesity. J. Nanotheranostics. 6, (2025). https://doi.org/10.3390/jnt6030021
2. Anand, S., Patel, T.N.: Integrating the metabolic and molecular circuits in diabetes, obesity and cancer: a comprehensive review. Discov. Oncol. 15, 779 (2024). https://doi.org/10.1007/s12672-024-01662-1
3. Anguita-Ruiz, A., Bustos-Aibar, M., Plaza-Díaz, J., Mendez-Gutierrez, A., Alcalá-Fdez, J., Aguilera, C.M., Ruiz-Ojeda, F.J.: Omics Approaches in Adipose Tissue and Skeletal Muscle Addressing the Role of

Extracellular Matrix in Obesity and Metabolic Dysfunction. Int. J. Mol. Sci. 22, 2756 (2021). https://doi.org/10.3390/ijms22052756
4. Ejemot-Nwadiaro, R.I., Betiang, P.A., Basajja, M.: Obesity and Climate Change: A Two-way Street with Global Health Implications. Obes. Med. 100623 (2025). https://doi.org/10.1016/j.obmed.2025.100623
5. De Campos, O.C., Udeozor, P.A., Nfona, S.O., Lawal, B.: Modulation of Lipogenesis by Tetracarpidium conophorum Nuts via SREBP-1/ACCA-1/FASN Inhibition in Monosodium-Glutamate-Induced Obesity in Rats. Nat. Prod. Commun. 20, 1934578X251344035 (2025). https://doi.org/10.1177/1934578X251344035
6. Ibiam, U.A., Omang, W.A., Udeozor, P.A., Umoru, G.U., Nwadum, S.K., Bawa, I., Mordi, J.C., Okoro, E.O., Obeten, U.N., Onwe, E.N., Zakari, S., Opotu, O.R., Aja, P.M.: Buchholzia coriacea Leaves Attenuated Dyslipidemia and Oxidative Stress in Hyperlipidemic Rats and Its Potential Targets In Silico. Pharm. Fronts. 05, e141–e152 (2023). https://doi.org/10.1055/s-0043-1772607
7. Uti, D.E., Atangwho, I.J., Omang, W.A., Alum, E.U., Obeten, U.N., Udeozor, P.A., Agada, S.A., Bawa, I., Ogbu, C.O.: Cytokines as key players in obesity low grade inflammation and related complications. Obes. Med. 54, 100585 (2025). https://doi.org/10.1016/j.obmed.2025.100585
8. Brancewicz, J., Wójcik, N., Sarnowska, Z., Robak, J., Król, M.: The Multifaceted Role of Macrophages in Biology and Diseases. Int. J. Mol. Sci. 26, 2107 (2025). https://doi.org/10.3390/ijms26052107
9. Guria, S., Hoory, A., Das, S., Chattopadhyay, D., Mukherjee, S.: Adipose tissue macrophages and their role in obesity-associated insulin resistance: an overview of the complex dynamics at play. Biosci. Rep. 43, BSR20220200 (2023). https://doi.org/10.1042/BSR20220200
10. Mussbacher, M., Derler, M., Basílio, J., Schmid, J.A.: NF-κB in monocytes and macrophages – an inflammatory master regulator in multitalented immune cells. Front. Immunol. 14, 1134661 (2023). https://doi.org/10.3389/fimmu.2023.1134661
11. Wen, P., Liu, L.: Functions of Macrophages, T Cells, and Neutrophils in the Synovial Microenvironment of Osteoarthritis. J. Inflamm. Res. 18, 15671–15686 (2025). https://doi.org/10.2147/JIR.S563253
12. Bhol, N.K., Bhanjadeo, M.M., Singh, A.K., Dash, U.C., Ojha, R.R., Majhi, S., Duttaroy, A.K., Jena, A.B.: The interplay between cytokines, inflammation, and antioxidants: mechanistic insights and therapeutic potentials of various antioxidants and anti-cytokine compounds. Biomed. Pharmacother. 178, 117177 (2024). https://doi.org/10.1016/j.biopha.2024.117177
13. Alum, E., Aloh, H., Obasi, D., Okoroh, P., Aniokete, U., & Emeruwa, A. (2025). Maternal Nutrition, Toxicants, and Epigenetic Programming of Obesity Across Generations. Diabetes Metabolic Syndrome and Obesity, Volume 18, 4873-4911. https://doi.org/10.2147/dmso.s579409
14. Izah, S.C., Betiang, P.A., Ainebyoona, C., Echegu, D.A.,: The Ketogenic Diet in Obesity Management: Friend or Foe? Cell Biochem. Biophys. (2025). https://doi.org/10.1007/s12013-025-01878-0
15. Lu, J., Liu, P., Cai, M., Lv, T., Zhang, M., Yin, K., Cheng, J., Zhang, G.: Recent progress in the pharmacotherapy for obesity. Eur. J. Pharmacol. 1002, 177850 (2025). https://doi.org/10.1016/j.ejphar.2025.177850
16. Umoru, G.U., Aja, P.M., Ugwu, O.P., Orji, O.U., Nwali, B.U., Ezeani, N.N., Edwin, N., Orinya, F.O.: Hepato-Protective Effect of Ethanol Leaf Extract of Datura stramonium in Alloxan-induced Diabetic Albino Rats. J. Chem. Soc. Niger. 47, (2022). https://doi.org/10.46602/jcsn.v47i5.819
17. Atangwho, I.J., Egba, S.I., Ikechukwu, G.C.: Natural Antidiabetic Agents: Current Evidence and Development Pathways from Medicinal Plants to Clinical use. Nat. Prod. Commun. 20, 1934578X251323393 (2025). https://doi.org/10.1177/1934578X251323393
18. Mollah, F., Khatun, M.M., Chowdhury, R., Bhuia, Md.S., Sultan, J.A., Situ, S.G., Hasan, Md.S.A., Kamli, H., Islam, M.T.: Therapeutic Promises of Bioactive Linarin, a Glycosylated Flavonoid: A Comprehensive Review With Mechanistic Insight. J. Trop. Med. 2025, 9989759 (2025). https://doi.org/10.1155/jotm/9989759
19. Uti, D.E., Alum, E.U., Atangwho, I.J., Ugwu, O.P.-C., Egbung, G.E., Aja, P.M.: Lipid-based nano-carriers for the delivery of anti-obesity natural compounds: advances in targeted delivery and precision therapeutics. J. Nanobiotechnology. 23, 336 (2025). https://doi.org/10.1186/s12951-025-03412-z
20. Ntaobeten, E., Obeten, U.N., Bawa, I., Agada, S.A., Ukam, C.I.-O., Egbung, G.E.: Antioxidants in cancer therapy mitigating lipid peroxidation without compromising treatment through nanotechnology. Discov. Nano. 20, 70 (2025). https://doi.org/10.1186/s11671-025-04248-0
21. Alexaki, V.I.: Adipose tissue-derived mediators of systemic inflammation and metabolic control. Curr. Opin. Endocr. Metab. Res. 37, 100560 (2024). https://doi.org/10.1016/j.coemr.2024.100560
22. Bera, R., Pathak, S., Srivastava, P., Ghosh, M., Sharma, A., Ahmed, N.Z., Karwasra, R., Akram, U., Kumar, P., Sharma, B., Sharma, N.: Biomimetic nanocarriers for the therapy and management of intestinal inflammations. Int. J. Pharm. X. 10, 100377 (2025). https://doi.org/10.1016/j.ijpx.2025.100377

23. Chait, A., den Hartigh, L.J.: Adipose Tissue Distribution, Inflammation and Its Metabolic Consequences, Including Diabetes and Cardiovascular Disease. Front. Cardiovasc. Med. 7, 22 (2020). https://doi.org/10.3389/fcvm.2020.00022
24. Obasi, D.C., Abba, J.N., Aniokete, U.C., Okoroh, P.N., Akwari, A.Ak.: Evolving Paradigms in Nutrition Therapy for Diabetes: From Carbohydrate Counting to Precision Diets. Obes. Med. 100622 (2025). https://doi.org/10.1016/j.obmed.2025.100622
25. Omang, W.A., Wokoma, M.A., Oplekwu, R.I., Atangwho, I.J., Egbung, G.E.: Targeting CD44-Hyaluronic Acid Signalling in Obesity Treatment: Insights from Small Molecules and Nanobioconjugates. Nutr. Metab. Insights. 19, 11786388251408961 (2026). https://doi.org/10.1177/11786388251408961
26. Bešlo, D., Golubić, N., Rastija, V., Agić, D., Karnaš, M., Šubarić, D., Lučić, B.: Antioxidant Activity, Metabolism, and Bioavailability of Polyphenols in the Diet of Animals. Antioxidants. 12, 1141 (2023). https://doi.org/10.3390/antiox12061141
27. Ma, Z., Wang, S., Miao, W., Zhang, Z., Yu, L., Liu, S., Luo, Z., Liang, H., Yu, J., Huang, T., Li, M., Gao, J., Su, S., Li, Y., Zhou, L.: The Roles of Natural Alkaloids and Polyphenols in Lipid Metabolism: Therapeutic Implications and Potential Targets in Metabolic Diseases. Curr. Med. Chem. 30, 3649–3667 (2023). https://doi.org/10.2174/0929867330666221107095646
28. Bertoncini-Silva, C., Vlad, A., Ricciarelli, R., Giacomo Fassini, P., Suen, V.M.M., Zingg, J.-M.: Enhancing the Bioavailability and Bioactivity of Curcumin for Disease Prevention and Treatment. Antioxidants. 13, 331 (2024). https://doi.org/10.3390/antiox13030331
29. Seth, A., Iyyuni, S., Sharma, S., Sethi, R., Nath, S., Imeokparia, M.: Curcumin as a Supportive Therapy in Type 2 Diabetic Patients. Adv. Public Health. 2024, 8563066 (2024). https://doi.org/10.1155/2024/8563066
30. Zhang, D., Fu, M., Gao, S.-H., Liu, J.-L.: Curcumin and Diabetes: A Systematic Review. Evid.-Based Complement. Altern. Med. ECAM. 2013, 636053 (2013). https://doi.org/10.1155/2013/636053
31. Bouyahya, A., Balahbib, A., Khalid, A., Makeen, H.A., Alhazmi, H.A., Albratty, M., Hermansyah, A., Ming, L.C., Goh, K.W., El Omari, N.: Clinical applications and mechanism insights of natural flavonoids against type 2 diabetes mellitus. Heliyon. 10, e29718 (2024). https://doi.org/10.1016/j.heliyon.2024.e29718
32. Zahra, M., Abrahamse, H., George, B.P.: Flavonoids: Antioxidant Powerhouses and Their Role in Nanomedicine. Antioxidants. 13, 922 (2024). https://doi.org/10.3390/antiox13080922
33. Hanis, N., Ismail, N.A., Ali, E.Z.: Systematic review on effectiveness of flavonoids against hypercholesterolemia: Insights from in-silico, in-vitro, and in-vivo studies. Food Chem. Adv. 7, 100981 (2025). https://doi.org/10.1016/j.focha.2025.100981
34. Dinh, T.C., Thi Phuong, T.N., Minh, L.B., Minh Thuc, V.T., Bac, N.D., Van Tien, N., Pham, V.H., Show, P.L., Tao, Y., Nhu Ngoc, V.T., Bich Ngoc, N.T., Jurgoński, A., Thimiri Govinda Raj, D.B., Van Tu, P., Ha, V.N., Czarzasta, J., Chu, D.-T.: The effects of green tea on lipid metabolism and its potential applications for obesity and related metabolic disorders - An existing update. Diabetes Metab. Syndr. Clin. Res. Rev. 13, 1667–1673 (2019). https://doi.org/10.1016/j.dsx.2019.03.021
35. Alum, E.U.: Role of phytochemicals in cardiovascular disease management: Insights into mechanisms, efficacy, and clinical application. Phytomedicine Plus. 5, 100695 (2025). https://doi.org/10.1016/j.phyplu.2024.100695
36. Spanoudaki, M., Chrysafi, M., Papadopoulou, S.K., Tsourouflis, G., Pritsa, A., Giaginis, C.: Naturally Occurring Compounds Targeting Peroxisome Proliferator Receptors: Potential Molecular Mechanisms and Future Perspectives for Promoting Human Health. Appl. Sci. 14, (2024). https://doi.org/10.3390/app14219994
37. Phytonutrients in the management of lipids metabolism. In: The Role of Phytonutrients in Metabolic Disorders. pp. 195–236. Academic Press (2022)
38. Adhikari, B.: Roles of Alkaloids from Medicinal Plants in the Management of Diabetes Mellitus. J. Chem. 2021, 2691525 (2021). https://doi.org/10.1155/2021/2691525
39. Kasimir, M., Wolbeck, A., Behrens, M., Humpf, H.-U.: Intestinal Metabolism of Selected Steroidal Glycoalkaloids in the Pig Cecum Model. ACS Omega. 8, 18266–18274 (2023). https://doi.org/10.1021/acsomega.3c01990
40. Anjum, S., Ishaque, S., Fatima, H., Farooq, W., Hano, C., Abbasi, B.H., Anjum, I.: Emerging Applications of Nanotechnology in Healthcare Systems: Grand Challenges and Perspectives. Pharmaceuticals. 14, 707 (2021). https://doi.org/10.3390/ph14080707
41. Nwuruku, O.A., Ugwu, O.P.-C., Uti, D.E., Edwin, N.: Harnessing nature: plant-derived nanocarriers for targeted drug delivery in cancer therapy. Phytomedicine Plus. 5, 100828 (2025). https://doi.org/10.1016/j.phyplu.2025.100828

42. Priya, Chaudhary, A., Rejeeth, C., Kumar, S., Ding, X., Sharma, A.: Exploring plant-based metallic nanoparticles for advanced medicinal application in diabetes. Nanotechnol. 8, 100243 (2025). https://doi.org/10.1016/j.nxnano.2025.100243
43. Unnisa, A., Greig, N.H., Kamal, M.A.: Nanotechnology-based gene therapy as a credible tool in the treatment of Alzheimer's disease. Neural Regen. Res. 18, 2127–2133 (2023). https://doi.org/10.4103/1673-5374.369096
44. Eltaib, L.: Polymeric Nanoparticles in Targeted Drug Delivery: Unveiling the Impact of Polymer Characterization and Fabrication. Polymers. 17, (2025). https://doi.org/10.3390/polym17070833
45. Herdiana, Y., Wathoni, N., Shamsuddin, S., Muchtaridi, M.: Scale-up polymeric-based nanoparticles drug delivery systems: Development and challenges. OpenNano. 7, 100048 (2022). https://doi.org/10.1016/j.onano.2022.100048
46. Zielińska, A., Carreiró, F., Oliveira, A.M., Neves, A., Pires, B., Venkatesh, D.N., Durazzo, A., Lucarini, M., Eder, P., Silva, A.M., Santini, A., Souto, E.B.: Polymeric Nanoparticles: Production, Characterization, Toxicology and Ecotoxicology. Molecules. 25, 3731 (2020). https://doi.org/10.3390/molecules25163731
47. Anwar, D.M., Hedeya, H.Y., Ghozlan, S.H., Ewas, B.M., Khattab, S.N.: Surface-modified lipid-based nanocarriers as a pivotal delivery approach for cancer therapy: application and recent advances in targeted cancer treatment. Beni-Suef Univ. J. Basic Appl. Sci. 13, 106 (2024). https://doi.org/10.1186/s43088-024-00566-x
48. Shehata, M.M.: Anticancer lipid-based drug delivery systems: Basic knowledge and recent applications. Nano TransMed. 3, 100054 (2024). https://doi.org/10.1016/j.ntm.2024.100054
49. Mohite, P., Singh, S., Pawar, A., Sangale, A., Prajapati, B.G.: Lipid-based oral formulation in capsules to improve the delivery of poorly water-soluble drugs. Front. Drug Deliv. 3, (2023). https://doi.org/10.3389/fddev.2023.1232012
50. Lorenzett, A.K.P., de Lima, V.A., da Fonseca, C.O.P., Mainardes, R.M.: Nanoemulsions and Microemulsions for Intranasal Drug Delivery: A Bibliometric Analysis and Emerging Trends (2004–2024). Pharmaceutics. 17, 1104 (2025). https://doi.org/10.3390/pharmaceutics17091104
51. Zeinali, R., Zaeifi, D., Zolfaghari-Moghaddam, S.Y., Paul, M.K., Biazar, E.: Current Advances in Nanocarriers for Cancer Therapy. Int. J. Nanomedicine. 20, 12217–12262 (2025). https://doi.org/10.2147/IJN.S548088
52. Hou, J., Xue, Z., Chen, Y., Li, J., Yue, X., Zhang, Y., Gao, J., Hao, Y., Shen, J.: Development of Stimuli-Responsive Polymeric Nanomedicines in Hypoxic Tumors and Their Therapeutic Promise in Oral Cancer. Polymers. 17, (2025). https://doi.org/10.3390/polym17081010
53. Lee, H., Rho, W.-Y., Kim, Y.-H., Chang, H., Jun, B.-H.: CRISPR-Cas9 Gene Therapy: Non-Viral Delivery and Stimuli-Responsive Nanoformulations. Molecules. 30, 542 (2025). https://doi.org/10.3390/molecules30030542
54. Yang, J., des Rieux, A., Malfanti, A.: Stimuli-Responsive Nanomedicines for the Treatment of Non-cancer Related Inflammatory Diseases. ACS Nano. 19, 15189–15219 (2025). https://doi.org/10.1021/acsnano.5c00700
55. Alghamdi, M.A., Fallica, A.N., Virzì, N., Kesharwani, P., Pittalà, V., Greish, K.: The Promise of Nanotechnology in Personalized Medicine. J. Pers. Med. 12, 673 (2022). https://doi.org/10.3390/jpm12050673
56. Feng, J.: Role of curcumin in altering gut microbiota for anti-obesity and anti-hyperlipidemic effects. Front. Microbiol. 16, (2025). https://doi.org/10.3389/fmicb.2025.1625098
57. Alshammari, E.M.: Curcumin-based biocompatible nanocarriers: a contemporary perspective in functional foods and biomedical applications. Discov. Nano. 20, 226 (2025). https://doi.org/10.1186/s11671-025-04379-4
58. Mahjabeen, W., Khan, D.A., Mirza, S.A.: Role of resveratrol supplementation in regulation of glucose hemostasis, inflammation and oxidative stress in patients with diabetes mellitus type 2: A randomized, placebo-controlled trial. Complement. Ther. Med. 66, 102819 (2022). https://doi.org/10.1016/j.ctim.2022.102819
59. Zhu, X., Wu, C., Qiu, S., Yuan, X., Li, L.: Effects of resveratrol on glucose control and insulin sensitivity in subjects with type 2 diabetes: systematic review and meta-analysis. Nutr. Metab. 14, 60 (2017). https://doi.org/10.1186/s12986-017-0217-z
60. Antonelli, A., Palma, F.: Nanocarrier-Based Delivery Systems for Natural Compounds Across Research Stages. Materials. 18, 4960 (2025). https://doi.org/10.3390/ma18214960

Open Access
Online ISSN: 2992-5487
Print ISSN: 2992-6068

NIJEP Publications

CITE AS: Mugisha Emmanuel K. (2026). Nanotechnology-Driven Delivery of Natural Anti-Inflammatory Compounds for Obesity Management. NEWPORT INTERNATIONAL JOURNAL OF ENGINEERING AND PHYSICAL SCIENCES,6(1): 30-37.
https://doi.org/10.59298/NIJEP/2026/613037